[A18-31] Ertugliflozin/sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Last updated 06.09.2018
Project no.:
A18-31
Commission:
Commission awarded on 09.05.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adults inadequately controlled by treatment with at least two blood-glucose lowering drugs (except insulin; here: metformin and/or a sulphonylurea and ertugliflozin or sitagliptin)
No study data; added benefit not proven in comparison with the appropriate comparator therapy
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2018-08-15.After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.